- Market Size (2026)
- USD 5.0 Bn
- Forecast (2036)
- USD 10.0 Bn
- CAGR (2026 to 2036)
- 7.3%
Sexually Transmitted Diseases Diagnostics Market Size, Market Forecast and Outlook By FMI
The sexually transmitted diseases diagnostics market was valued at USD 4.6 billion in 2025. The market is set to reach USD 5.0 billion by 2026-end and grow at a CAGR of 7.3% between 2026-2036 to reach USD 10.0 billion by 2036.
Summary of the Sexually Transmitted Diseases Diagnostics Market
- Demand and Growth Drivers
- Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for sexually transmitted diseases diagnostics products across hospitals and specialty care settings.
- Regulatory approvals for expanded clinical applications are broadening the addressable patient population and creating incremental demand in established and emerging treatment pathways.
- Reimbursement coverage expansion in East Asia and South Asia is reducing financial barriers to clinical adoption, enabling sexually transmitted diseases diagnostics access in markets where volumes have been constrained.
- Product and Segment View
- Laboratory Devices account for 67.6% of the Device segment in 2026, supported by high clinical utilization.
- Laboratory represents 63.7% of the Location segment, reflecting established procedural protocols and broad clinical adoption.
- Secondary segments are growing as adoption expands across additional application categories and end-use environments.
- Geography and Competitive Outlook
- India leads country-level growth at 6.9%, supported by expanding healthcare infrastructure and increasing treatment access.
- North America remains the largest regional market, with strong demand from established clinical and research institutions.
- F. Hoffmann-La Roche Ltd leads at an estimated 22.0% market share, supported by broad product portfolio and established institutional procurement relationships.
- Analyst Opinion
- The sexually transmitted diseases diagnostics market is transitioning from a specialized clinical category into a more established treatment infrastructure segment as clinical evidence and reimbursement coverage expand.
- Adoption is shaped by the convergence of expanding clinical indications, reimbursement coverage growth, and the operational need for reliable treatment outcomes.
- Pricing pressure from hospital procurement teams and group purchasing organizations is compressing margins, shifting competitive differentiation toward clinical evidence, workflow integration, and regulatory-cleared product breadth.
- Companies that can combine broad indication coverage, validated clinical protocols, and institutional procurement relationships are positioned to capture growing procedural volume during the forecast period.
Key Takeaways, Market Size, and Forecast
- The Sexually Transmitted Diseases Diagnostics Market was valued at USD 4.63 billion in 2025.
- By 2036, the Sexually Transmitted Diseases Diagnostics Market is expected to be worth USD 10.05 billion.
- From 2026 to 2036, the market is projected to expand at a CAGR of 7.3%.
- The market is projected to create an incremental opportunity of USD 5.08 billion between 2026 and 2036.
- In 2026, Laboratory Devices is expected to account for 67.6% of the Device segment, driven by established clinical adoption and treatment protocol integration.
- India (6.9%) and China (6.1%) are two of the fastest growing markets in the world.
Sexually Transmitted Diseases Diagnostics Market Definition
The sexually transmitted diseases diagnostics market encompasses all commercially traded sexually transmitted diseases diagnostics products categorized by diagnostic test (cultural/isolated organisms, molecular test, immunology assay, other types of testing), by device (laboratory devices, point of sales), by disease (gonorrhea, syphilis, chlamydia, herpes simplex virus, human papillomavirus, others), by location (laboratory, point of care), by end user (hospitals, clinics, diagnostic labs, homecare setting, other). Products are used across hospitals, specialty clinics, and research settings for clinical treatment and diagnostic applications.
Sexually Transmitted Diseases Diagnostics Market Inclusions
Market scope covers all commercially traded sexually transmitted diseases diagnostics products categorized by diagnostic test (cultural/isolated organisms, molecular test, immunology assay, other types of testing), by device (laboratory devices, point of sales), by disease (gonorrhea, syphilis, chlamydia, herpes simplex virus, human papillomavirus, others), by location (laboratory, point of care), by end user (hospitals, clinics, diagnostic labs, homecare setting, other). Revenue is tracked from 2026 to 2036.
Sexually Transmitted Diseases Diagnostics Market Exclusions
The scope does not include general medical devices or therapeutic products unrelated to the specific sexually transmitted diseases diagnostics product category, or components sold as raw materials without end-use specification.
Sexually Transmitted Diseases Diagnostics Market Research Methodology
- Primary Research: Interviews with clinical practitioners, hospital procurement teams, and device manufacturers across key markets in North America, Europe, and East Asia.
- Desk Research: Analysis of regulatory approval databases, reimbursement coding systems, clinical trial registries, and published treatment guidelines.
- Market Sizing and Forecasting: Bottom-up aggregation from procedural volumes and clinical utilization rates across primary segment and geographic categories, with regional adoption curves.
- Data Validation: Cross-checked quarterly against regulatory approval timelines, clinical registry data, and manufacturer revenue disclosures.
Why is the Sexually Transmitted Diseases Diagnostics Market Growing?
- Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for sexually transmitted diseases diagnostics products across hospitals and specialty care sett.
- Regulatory approvals for expanded clinical applications are broadening the addressable patient population and creating incremental demand in established and emerging treatment pathways.
- India leads with 6.9% growth, reflecting healthcare infrastructure expansion and increasing treatment access across hospital networks.
Clinical Adoption and Treatment Protocol Integration
Demand for sexually transmitted diseases diagnostics products reflects the growing clinical evidence base and expanding treatment indications that are broadening the addressable patient population. Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for sexually transmitted diseases diagnostics products across hospitals and specialty care settings. Clinical adoption is supported by published treatment protocols, favorable outcomes data, and growing physician familiarity with product capabilities across established and emerging indications.
Reimbursement and Access Expansion
Reimbursement coverage expansion across developed and emerging markets is reducing financial barriers to adoption. Established reimbursement frameworks in North America and Western Europe support procedural volumes, while progressive coverage expansion in East Asia and South Asia is opening new growth channels.
Competitive Dynamics and Pricing Pressure
High per-unit cost and the requirement for specialized clinical infrastructure limit adoption in resource-constrained healthcare settings and community-level facilities. Hospital procurement consolidation through group purchasing organizations is creating competitive pressure on device pricing, which is shifting manufacturer focus toward clinical differentiation, service contracts, and outcome-based value propositions.
Market Segmentation Analysis
- Laboratory Devices account for 67.6% of the Device segment in 2026, supported by high clinical utilization.
- Laboratory represents 63.7% of the Location segment, reflecting established procedural protocols and broad clinical adoption.
- Secondary segments are growing as adoption expands across additional application categories and end-use environments.
The sexually transmitted diseases diagnostics market is segmented by diagnostic test (cultural/isolated organisms, molecular test, immunology assay, other types of testing), by device (laboratory devices, point of sales), by disease (gonorrhea, syphilis, chlamydia, herpes simplex virus, human papillomavirus, others), by location (laboratory, point of care), by end user (hospitals, clinics, diagnostic labs, homecare setting, other).
Insights into the Cultural/Isolated Organisms Diagnostic Test Segment
Cultural/Isolated Organisms are the leading category within the Diagnostic Test segment. Demand is concentrated in clinical settings where established treatment protocols and procedural infrastructure support regular utilization. The category maintains its leading position through broad clinical applicability and favorable cost-effectiveness relative to alternatives.
Procurement is shaped by institutional purchasing agreements and volume-based pricing through hospital group purchasing organizations. Other categories within the diagnostic test segment, including Molecular Test, Immunology Assay, Other Types of Testing, serve additional clinical applications and treatment pathways.
Insights into the Laboratory Devices Device Segment
Laboratory Devices account for 67.6% of the Device segment in 2026. Demand is concentrated in clinical settings where established treatment protocols and procedural infrastructure support regular utilization. The category maintains its leading position through broad clinical applicability and favorable cost-effectiveness relative to alternatives.
Procurement is shaped by institutional purchasing agreements and volume-based pricing through hospital group purchasing organizations. Other categories within the device segment, including Point of Sales, serve additional clinical applications and treatment pathways.
Sexually Transmitted Diseases Diagnostics Market Drivers, Restraints, and Opportunities
- Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for sexually transmitted diseases diagnostics products across hospitals and specialty care settings.
- High per-unit cost and the requirement for specialized clinical infrastructure limit adoption in resource-constrained healthcare settings and community-level facilities.
- Expansion of clinical evidence into new indications represents a structural growth opportunity, as each validated application increases the addressable patient base.
The sexually transmitted diseases diagnostics market grows on the back of expanding clinical indications, reimbursement coverage gains, and infrastructure investment in treatment delivery. High per-unit costs and infrastructure requirements constrain adoption in resource-limited settings.
Clinical Indication and Procedural Volume Growth
Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for sexually transmitted diseases diagnostics products across hospitals and specialty care settings.
Cost and Infrastructure Constraints
High per-unit cost and the requirement for specialized clinical infrastructure limit adoption in resource-constrained healthcare settings and community-level facilities.
Reimbursement and Access Drivers
Reimbursement coverage expansion in East Asia and South Asia is reducing financial barriers to clinical adoption, enabling sexually transmitted diseases diagnostics access in markets where volumes have been constrained.
Geographic Expansion Opportunity
Healthcare infrastructure investment in China, India, and other emerging markets is expanding the installed base of clinical equipment and trained specialists, creating new procedural volume for sexually transmitted diseases diagnostics products.
Analysis of Sexually Transmitted Diseases Diagnostics Market By Key Countries
.webp "Top Country Growth Comparison Sexually Transmitted Diseases Diagnostics Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| India | 6.9% |
| China | 6.1% |
| South Korea | 4.8% |
| USA | 3.4% |
| France | 3.1% |
| UK | 2.2% |
| Germany | 1.9% |
Source: FMI analysis based on primary research and proprietary forecasting model
- India leads at 6.9% CAGR, reflecting expanding healthcare infrastructure and increasing treatment access.
- China at 6.1% sustains growth through established clinical programs and expanding reimbursement coverage.
- South Korea at 4.8% shows growth through established clinical programs and expanding reimbursement coverage.
- USA at 3.4% shows growth through established clinical programs and expanding reimbursement coverage.
The global sexually transmitted diseases diagnostics market is projected to grow at a CAGR of 7.3% from 2026 to 2036. Growth rates vary by country based on healthcare infrastructure capacity, reimbursement coverage, clinical adoption patterns, and disease prevalence.
Demand Outlook for Sexually Transmitted Diseases Diagnostics Market in India
India is projected to grow at 6.9% through 2036. Growth is shaped by expanding hospital infrastructure, increasing clinical adoption, and progressive reimbursement coverage for sexually transmitted diseases diagnostics products.
- Hospital infrastructure expansion enables increased procedural capacity.
- Reimbursement coverage expansion supports broader patient access.
- Growing specialist training programs support adoption in secondary care settings.
Future Outlook for Sexually Transmitted Diseases Diagnostics Market in China
China is projected to grow at 6.1% through 2036. Growth is shaped by expanding hospital infrastructure, increasing clinical adoption, and progressive reimbursement coverage for sexually transmitted diseases diagnostics products.
- Hospital infrastructure expansion enables increased procedural capacity.
- Reimbursement coverage expansion supports broader patient access.
- Growing specialist training programs support adoption in secondary care settings.
Opportunity Analysis of Sexually Transmitted Diseases Diagnostics Market in South Korea
South Korea is projected to grow at 4.8% through 2036. Growth is shaped by expanding hospital infrastructure, increasing clinical adoption, and progressive reimbursement coverage for sexually transmitted diseases diagnostics products.
- Established clinical programs maintain steady procedural volumes.
- Reimbursement coverage expansion supports broader patient access.
- Growing specialist training programs support adoption in secondary care settings.
In-depth Analysis of Sexually Transmitted Diseases Diagnostics Market in USA
USA is projected to grow at 3.4% through 2036. Demand is supported by healthcare modernization, growing specialist availability, and increasing treatment access for sexually transmitted diseases diagnostics products.
- Established clinical programs maintain steady procedural volumes.
- Institutional procurement channels sustain product demand.
- Growing specialist training programs support adoption in secondary care settings.
Sales Analysis of Sexually Transmitted Diseases Diagnostics Market in France
France is projected to grow at 3.1% through 2036. Demand is supported by healthcare modernization, growing specialist availability, and increasing treatment access for sexually transmitted diseases diagnostics products.
- Established clinical programs maintain steady procedural volumes.
- Institutional procurement channels sustain product demand.
- Clinical evidence expansion supports adoption across additional treatment pathways.
In-depth Analysis of Sexually Transmitted Diseases Diagnostics Market in UK
UK is projected to grow at 2.2% through 2036. Demand is supported by healthcare modernization, growing specialist availability, and increasing treatment access for sexually transmitted diseases diagnostics products.
- Established clinical programs maintain steady procedural volumes.
- Institutional procurement channels sustain product demand.
- Clinical evidence expansion supports adoption across additional treatment pathways.
Competitive Landscape and Strategic Positioning
- F. Hoffmann-La Roche Ltd leads at an estimated 22.0% market share, supported by a broad product portfolio and established institutional procurement relationships.
- Abbott and Thermo Fisher Scientific Inc. compete on specialized product offerings and clinical evidence depth.
- CERTEST BIOTEC and OPERON are expanding into emerging market segments.
F. Hoffmann-La Roche Ltd holds an estimated 22.0% share, supported by a comprehensive product portfolio, global manufacturing infrastructure, and established relationships with hospital procurement teams. Abbott competes on clinical evidence depth, regulatory clearances, and product specialization.
The competitive landscape includes both large medical device companies with broad portfolios and specialized manufacturers focused on specific product categories or indications. Thermo Fisher Scientific Inc. and CERTEST BIOTEC serve specific clinical applications and regional markets.
Barriers to entry include regulatory approval requirements for medical devices, the need for clinical evidence from controlled trials, established hospital procurement relationships, and the requirement for manufacturing quality systems compliance. Strategic priorities center on expanding indication coverage, improving clinical outcomes data, and strengthening institutional procurement positions.
Key Companies in the Sexually Transmitted Diseases Diagnostics Market
Key global companies leading the sexually transmitted diseases diagnostics market include:
- F. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., CERTEST BIOTEC hold leading positions with broad product portfolios, established regulatory clearances, and global institutional procurement networks.
- OPERON, Bio-Rad laboratories, Qaigen Inc., Diasorin SPA compete on specialized product offerings, regional clinical expertise, and focused indication coverage.
- MedMira Inc., Hologic, Cepheid, BioMeriuex serve emerging segments and specialized applications, representing potential growth competitors.
Competitive Benchmarking: Sexually Transmitted Diseases Diagnostics Market
| Company | Product Portfolio | Clinical Evidence | Institutional Access | Geographic Coverage |
|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd | High | High | Strong | Global |
| Abbott | High | High | Strong | Global |
| Thermo Fisher Scientific Inc. | Medium | Medium | Moderate | Global |
| CERTEST BIOTEC | Medium | Medium | Moderate | Global |
| OPERON | Medium | Medium | Moderate | Regional |
| Bio-Rad laboratories | Medium | Medium | Moderate | Regional |
| Qaigen Inc. | Low | Low | Low | Regional |
| Diasorin SPA | Low | Low | Low | Regional |
| MedMira Inc. | Low | Low | Low | Regional |
| Hologic | Low | Low | Low | Regional |
Source: Future Market Insights competitive analysis, 2026.
Key Players in the Sexually Transmitted Diseases Diagnostics Market
Major Global Players
- F. Hoffmann-La Roche Ltd
- Abbott
- Thermo Fisher Scientific Inc.
- CERTEST BIOTEC
- OPERON
- Bio-Rad laboratories
Emerging Players/Startups
- Qaigen Inc.
- Diasorin SPA
- MedMira Inc.
- Hologic
- Cepheid
- BioMeriuex
Report Scope and Coverage
| Parameter | Details |
|---|---|
| Quantitative Units | USD 4.97 billion to USD 10.05 billion, at a CAGR of 7.3% |
| Market Definition | The sexually transmitted diseases diagnostics market encompasses sexually transmitted diseases diagnostics products used across clinical, research, and treatment settings. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | India, China, South Korea, USA, France, UK, 30 plus countries |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., CERTEST BIOTEC, OPERON, Bio-Rad laboratories, Qaigen Inc., Diasorin SPA, MedMira Inc., Hologic |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom-up and top-down methodology starting with verified procedural volume and clinical utilization data, projecting adoption velocity across segments and regions. |
Market Segmentation Analysis
Sexually Transmitted Diseases Diagnostics Market Segmented by Diagnostic Test:
- Cultural/Isolated Organisms
- Molecular Test
- Immunology Assay
- Other Types of Testing
Sexually Transmitted Diseases Diagnostics Market Segmented by Device:
- Laboratory Devices
- Point of Sales
Sexually Transmitted Diseases Diagnostics Market Segmented by Disease:
- Gonorrhea
- Syphilis
- Chlamydia
- Herpes Simplex Virus
- Human Papillomavirus
- Others
Sexually Transmitted Diseases Diagnostics Market Segmented by Location:
- Laboratory
- Point of Care
Sexually Transmitted Diseases Diagnostics Market Segmented by End User:
- Hospitals
- Clinics
- Diagnostic Labs
- Homecare Setting
- Other
Sexually Transmitted Diseases Diagnostics Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- 1. World Health Organization. (2025). Global Health Observatory: Disease Burden and Treatment Access Statistics. WHO.
- 2. USA Food and Drug Administration. (2025). Medical Device Approvals and Clearances Database. FDA.
- 3. European Medicines Agency. (2024). Medical Device Regulation: Clinical Evidence and Performance Requirements. EMA.
- 4. Centers for Medicare and Medicaid Services. (2025). National Coverage Determinations for Medical Devices and Procedures. CMS.
- 5. National Institutes of Health. (2024). Clinical Trial Registry and Treatment Outcomes Database. NIH.
This bibliography is provided for reader reference.
This Report Answers
- Estimating the size of the sexually transmitted diseases diagnostics market and revenue potential from 2026 to 2036.
- Segmentation by diagnostic test (cultural/isolated organisms, molecular test, immunology assay, other types of testing), by device (laboratory devices, point of sales), by disease (gonorrhea, syphilis, chlamydia, herpes simplex virus, human papillomavirus, others), by location (laboratory, point of care), by end user (hospitals, clinics, diagnostic labs, homecare setting, other).
- Regional insights across more than 30 markets including key growth countries.
- Analysis of clinical adoption trends, treatment protocols, and procedural dynamics.
- Assessment of the competitive landscape including leading manufacturers and emerging players.
- Identification of investment opportunities across clinical, research, and geographic expansion segments.
- Tracking of regulatory approvals, reimbursement changes, and clinical evidence developments.
- Delivery of data in PDF and Excel formats.
Frequently Asked Questions
What is the global market demand for Sexually Transmitted Diseases Diagnostics in 2026?
In 2026, the global sexually transmitted diseases diagnostics market is expected to be worth USD 4.97 billion.
How big will the Sexually Transmitted Diseases Diagnostics Market be in 2036?
By 2036, the sexually transmitted diseases diagnostics market is expected to be worth USD 10.05 billion.
How much is demand for Sexually Transmitted Diseases Diagnostics expected to grow between 2026 and 2036?
Between 2026 and 2036, the demand for sexually transmitted diseases diagnostics is expected to grow at a CAGR of 7.3%.
Which Device is expected to lead in 2026?
Laboratory Devices are expected to account for 67.6% of the Device segment in 2026, supported by established clinical adoption and strong procedural demand.
What is causing demand to rise in India?
India is projected to grow at 6.9% through 2036, reflecting expanding healthcare infrastructure, increasing treatment access, and progressive reimbursement coverage.
What is causing demand to rise in China?
China is projected to grow at 6.1% through 2036, supported by healthcare modernization, growing specialist availability, and increasing treatment access.
What does this report mean by Sexually Transmitted Diseases Diagnostics Market definition?
The sexually transmitted diseases diagnostics market includes sexually transmitted diseases diagnostics products used across clinical, research, and treatment settings.
How does FMI make the Sexually Transmitted Diseases Diagnostics forecast and check it?
Forecasting models use a hybrid bottom-up and top-down approach, starting with verified procedural volume and clinical utilization data, and cross-referencing against regulatory approval databases, clinical registry data, and manufacturer disclosures.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- FMI Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Diagnostic Test
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Diagnostic Test , 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Diagnostic Test , 2026 to 2036
- Cultural/Isolated Organisms
- Molecular Test
- Immunology Assay
- Other Types of Testing
- Cultural/Isolated Organisms
- Y-o-Y Growth Trend Analysis By Diagnostic Test , 2021 to 2025
- Absolute $ Opportunity Analysis By Diagnostic Test , 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Device
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Device, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Device, 2026 to 2036
- Laboratory Devices
- Point of Sales
- Laboratory Devices
- Y-o-Y Growth Trend Analysis By Device, 2021 to 2025
- Absolute $ Opportunity Analysis By Device, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Disease
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Disease, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Disease, 2026 to 2036
- Gonorrhea
- Syphilis
- Chlamydia
- Herpes Simplex Virus
- Human Papillomavirus
- Others
- Gonorrhea
- Y-o-Y Growth Trend Analysis By Disease, 2021 to 2025
- Absolute $ Opportunity Analysis By Disease, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Location
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Location, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Location, 2026 to 2036
- Laboratory
- Point of Care
- Laboratory
- Y-o-Y Growth Trend Analysis By Location, 2021 to 2025
- Absolute $ Opportunity Analysis By Location, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End User
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End User, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End User, 2026 to 2036
- Hospitals
- Clinics
- Diagnostic Labs
- Homecare Setting
- Other
- Hospitals
- Y-o-Y Growth Trend Analysis By End User, 2021 to 2025
- Absolute $ Opportunity Analysis By End User, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Diagnostic Test
- By Device
- By Disease
- By Location
- By End User
- Competition Analysis
- Competition Deep Dive
- F. Hoffmann-La Roche Ltd
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Abbott
- Thermo Fisher Scientific Inc.
- CERTEST BIOTEC
- OPERON
- Bio-Rad laboratories
- Qaigen Inc.
- Diasorin SPA
- MedMira Inc.
- Hologic
- Cepheid
- BioMeriuex
- F. Hoffmann-La Roche Ltd
- Competition Deep Dive
- Assumptions & Acronyms Used
